Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Guanethidine monosulfate [antihypertensive] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 10 mg/1 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Guanethidine monosulfate [eye] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 3 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 2 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 1 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 0,5 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 0,25 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Guanethidine monosulfate 10 mg and hydrochlorothiazide 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat + hydrochlorthiazid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 0,25 % + adrenalin 0,05 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 1 % + adrenalin 0,5 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
guanethidinmonosulfat 0,5 % + adrenalin 0,1 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Adrenaline 2 mg/mL and guanethidine monosulfate 10 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Product containing precisely guanethidine monosulfate 10 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Guanethidine monosulfate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
|
Product containing precisely guanethidine monosulfate 10 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 10 mg and hydrochlorothiazide 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 10 mg and hydrochlorothiazide 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Guanethidine monosulfate 10 mg and hydrochlorothiazide 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
2 |
Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
2 |
Adrenaline 2 mg/mL and guanethidine monosulfate 10 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Adrenaline 2 mg/mL and guanethidine monosulfate 10 mg/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 milliliter conventional release solution for injection ampule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Product containing precisely guanethidine monosulfate 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |
Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Guanethidine monosulfate |
Inferred relationship |
Some |
1 |